BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, April 29, 2024
See today's BioWorld
Home
» Hutchison's fruquintinib meets phase III study endpoints in CRC
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Hutchison's fruquintinib meets phase III study endpoints in CRC
March 7, 2017
By
Shannon Ellis
No Comments
SHANGHAI – Hutchison Medipharma Ltd. (Chi-Med) announced its first phase III win with fruquintinib, a targeted VEGFR inhibitor studied as a third-line therapy in 416 Chinese patients with colorectal cancer (CRC).
BioWorld